Astera Labs, Inc. (Nasdaq: ALAB), a global leader in
semiconductor-based connectivity solutions for cloud and AI
infrastructure, today announced preliminary financial results for
the fourth quarter and full fiscal year 2024, ended December 31,
2024.
“Astera Labs delivered strong Q4 results, with revenue growing
25% versus the previous quarter, and capped off a stellar 2024 with
242% revenue growth year-over-year,” said Jitendra Mohan, Astera
Labs’ Chief Executive Officer. “The revenue growth in 2024 was
largely driven by Aries PCIe Retimer products, with Taurus Smart
Cable Modules for Ethernet coming in strongly in Q4. We expect 2025
to be a breakout year as we enter a new phase of growth driven by
revenue from all four of our product families to support a diverse
set of customers and platforms. This includes our flagship Scorpio
Fabric products for head-node PCIe connectivity and backend AI
accelerator scale-up clustering.”
Fourth Quarter of Fiscal 2024 Financial
Highlights
GAAP Financial Results:
- Revenue of $141.1 million, up 25% sequentially and up 179%
year-over-year
- GAAP gross margin of 74.0%
- GAAP operating income of $0.1 million
- GAAP operating margin of 0.1%
- GAAP net income of $24.7 million
- GAAP diluted net earnings per share of $0.14
Non-GAAP Financial Results (excluding the impact of stock-based
compensation expense and the income tax effects of non-GAAP
adjustments):
- Non-GAAP gross margin of 74.1%
- Non-GAAP operating income of $48.4 million
- Non-GAAP operating margin of 34.3%
- Non-GAAP net income of $66.5 million
- Non-GAAP diluted earnings per share of $0.37
Full Year Fiscal 2024 Financial Highlights
GAAP Financial Results:
- Revenue of $396.3 million, up 242% year-over-year
- GAAP gross margin of 76.4%
- GAAP operating loss of $116.1 million
- GAAP operating margin of (29.3%)
- GAAP net loss of $83.4 million
- GAAP diluted net loss per share of $0.64
Non-GAAP and Non-GAAP Financial Results (excluding the impact of
stock-based compensation expense and the income tax effects of
non-GAAP adjustments):
- Non-GAAP gross margin of 76.6%
- Non-GAAP operating income of $119.6 million
- Non-GAAP operating margin of 30.2%
- Non-GAAP net income of $143.3 million
- Pro forma non-GAAP diluted earnings per share of $0.84
Full Year Fiscal 2024 Business Highlights
- Introduced new portfolio of Scorpio Smart Fabric Switches
purpose-built for AI infrastructure at cloud-scale. The Scorpio
Smart Fabric Switch family features two application-specific
product lines with a multi-generational roadmap, including the
P-Series for GPU-to-CPU/NIC/SSD PCIe Gen 6 connectivity and the
X-Series for platform-specific, back-end AI accelerator clustering.
Scorpio is currently shipping in pre-production quantities.
- Joined the Ultra Accelerator Link Consortium as a promoting
member on the Board of Directors. UALink technology will be used to
enable efficient high-speed scale-up connectivity between AI
accelerators within large and growing cluster sizes for AI
workloads. Astera Labs is well positioned to quickly contribute to
this new and compelling industry initiative to develop and advance
UALink technology.
- Demonstrated the industry’s first end-to-end PCIe optical
connectivity link to provide extended reach for larger,
disaggregated GPU clusters. PCIe over optics expands Astera Labs’
widely deployed and field-tested Aries family of Smart DSP retimers
and Smart Cable Modules (SCMs) to deliver robust PCIe and CXL
connectivity in chip-to-chip, box-to-box, and rack-to-rack
topologies throughout the data center.
- Expanded the widely deployed and field-tested Aries PCIe/CXL
Smart DSP Retimer portfolio with the introduction and initial
shipment of Aries 6 Retimers, the industry’s lowest power PCIe
6.x/CXL 3.x Retimer solution, to achieve higher bandwidth and
extended reach across complex AI and compute topologies.
- Shipped Aries PCIe/CXL Smart Cable Modules for Active
Electrical Cable applications to enable multi-rack GPU clustering
and low-latency memory fabric connectivity within AI
infrastructure. The solution drives seven meters of reach over
flexible copper cables to seamlessly and affordably interconnect
clusters of GPUs across rack enclosures.
- Showcased the first public demonstration of end-to-end
interoperability between a PCIe 6.x Switch and a PCIe 6.x SSD at
DesignCon 2025. The PCIe 6.x link-up was between an Astera Labs
Scorpio P-Series Fabric Switch and Micron’s PCIe 6.x SSDs and
showcased remarkable sequential read speeds exceeding 26GB/s.
First Quarter of Fiscal 2025 Financial
Outlook
Based on current business trends and conditions, Astera Labs
estimates the following:
GAAP Financial Outlook:
- Revenue within a range of $151 million to $155 million
- GAAP gross margin of approximately 74%
- GAAP operating expenses within a range of approximately $113
million to $114 million
- GAAP tax expense of approximately $3 million
- GAAP diluted earnings per share within a range of approximately
$0.03 to $0.04 on weighted-average diluted shares outstanding of
approximately 180 million
Non-GAAP Financial Outlook (excluding the impact of
approximately $47 million of stock-based compensation and including
approximately $3 million of additional income taxes):
- Non-GAAP gross margin of approximately 74%
- Non-GAAP operating expenses within a range of approximately $66
million to $67 million
- Non-GAAP tax rate of approximately 10%
- Non-GAAP diluted earnings per share within a range of
approximately $0.28 to $0.29 on non-GAAP weighted-average diluted
shares outstanding of approximately 180 million
Earnings Webcast and Conference CallAstera Labs
will host a conference call to review its financial results for the
fourth quarter and full year of fiscal 2024 and to discuss our
financial outlook today at 1:30 p.m. Pacific Time. Interested
parties may join the conference call by dialing 1-800-715-9871 and
using conference ID 5908687. The call will also be webcast and can
be accessed at the Astera Labs website at
https://ir.asteralabs.com/. The webcast will be recorded and
available for replay on the company’s website for the next six
months.
Discussion of Non-GAAP Financial MeasuresWe use
certain non-GAAP financial measures to supplement the performance
measures in our consolidated financial statements, which are
presented in accordance with GAAP. A reconciliation of these
non-GAAP measures to the closest GAAP measure can be found later in
this release. These non-GAAP financial measures include non-GAAP
gross profit, non-GAAP gross margin, non-GAAP operating expenses,
non-GAAP operating income (loss), non-GAAP operating margin,
non-GAAP tax rate, non-GAAP net income (loss), non-GAAP diluted
earnings (loss) per share, and non-GAAP weighted-average share
count. We use these non-GAAP financial measures for financial and
operational decision-making and as a means to assist us in
evaluating period-to-period comparisons. By excluding certain items
that may not be indicative of our recurring core operating results,
we believe that, non-GAAP gross profit, non-GAAP gross margin,
non-GAAP operating expenses, non-GAAP operating income (loss),
non-GAAP operating margin, non-GAAP tax rate, non-GAAP net income
(loss), non-GAAP pro forma diluted earnings (loss) per share, and
non-GAAP pro forma weighted-average share count provide meaningful
supplemental information regarding our performance. Accordingly, we
believe these non-GAAP financial measures are useful to investors
and others because they allow for additional information with
respect to financial measures used by management in its financial
and operational decision-making and they may be used by our
institutional investors and the analyst community to help them
analyze the health of our business. However, there are a number of
limitations related to the use of non-GAAP financial measures, and
these non-GAAP measures should be considered in addition to, not as
a substitute for or in isolation from, our financial results
prepared in accordance with GAAP. Other companies, including
companies in our industry, may calculate these non-GAAP financial
measures differently or not at all, which reduces their usefulness
as comparative measures.
No reconciliation is provided with respect to the
forward-looking non-GAAP financial measures included in our
non-GAAP financial outlook, as the GAAP measures are not accessible
on a forward-looking basis. As a result, we cannot reliably predict
all necessary components or their impact to reconcile such
financial measures without unreasonable effort. The events
necessitating a non-GAAP adjustment are inherently unpredictable
and may have a significant impact on our future GAAP financial
results.
We adjust the following items from one or more of our non-GAAP
financial measures:
Stock-based compensation expense We exclude stock-based
compensation expense, which is a non-cash expense, from certain of
our non-GAAP financial measures because we believe that excluding
this item provides meaningful supplemental information regarding
operational performance. In particular, companies calculate
non-cash stock-based compensation expense using a variety of
valuation methodologies and subjective assumptions. Moreover,
stock-based compensation expense is a non-cash charge that can vary
significantly from period to period for reasons that are unrelated
to our core operating performance, and therefore excluding this
item provides investors and other users of our financial
information with information that allows meaningful comparisons of
our business performance across periods.
Employer payroll taxes related to stock-based compensation
resulting from our IPO We exclude employer payroll taxes related to
the time-based vesting and net settlement of restricted stock units
in connection with our initial public offering (the “IPO”), because
this does not correlate to the operation of our business. We
believe that excluding this item provides meaningful supplemental
information regarding operational performance given the amount of
employer payroll tax-related items on employee stock transactions
was immaterial prior to our IPO.
Income tax effectThis represents the impact of the non-GAAP
adjustments on an after-tax basis and one-off discrete tax
adjustments that are unrelated to our core operating performance in
connection with the presentation of non-GAAP net income (loss) and
non-GAAP net income (loss) per diluted share. This approach is
designed to enhance investors’ ability to understand the impact of
our non-GAAP tax expense on our current operations, provide
improved modeling accuracy, and substantially reduce fluctuations
caused by GAAP to non-GAAP adjustments.
Non-GAAP pro forma weighted-average shares to compute non-GAAP
pro forma net income (loss) per share We present non-GAAP pro forma
weighted-average shares, assuming our redeemable convertible
preferred stock is converted from the beginning of each respective
periods presented, to provide meaningful supplemental information
regarding EPS trend on a consistent basis. All of our outstanding
redeemable preferred stock converted into the equivalent number of
shares of common stock in connection with our IPO.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements based on Astera Labs' current expectations.
The words "believe", "estimate", "expect", "intend", “may”,
"anticipate", "plan", "project", "will", and similar phrases as
they relate to Astera Labs are intended to identify such
forward-looking statements. These forward-looking statements
reflect the current views and assumptions of Astera
Labs and are subject to various risks and uncertainties that
could cause actual results to differ materially from expectations.
These forward-looking statements include but are not limited to,
statements regarding our future operating results, financial
position and guidance, including for the first quarter of fiscal
2025, our business strategy and plans, our objectives for future
operations, our development or delivery of new or enhanced products
and anticipated results of those products for our customers, our
competitive positioning, including to meet the connectivity market
opportunity in the future and initiative to advance UALink
technology, technological capabilities and plans, our plans to add
R&D talent and strategic IP blocks, and macroeconomic trends in
cloud and AI infrastructure. A variety of risks and factors that
are beyond our control could cause actual results to differ
materially from those in the forward-looking statements including,
without limitation: the competitive and cyclical nature of the
semiconductor industry; the concentration of our customer base; the
changes in demand for AI; the macroeconomic environment; risks that
demand and the supply chain may be adversely affected, including by
the imposition of tariffs by the United States and any
corresponding retaliatory tariffs, changes in political policies,
military conflict (such as between Russia/Ukraine and
Israel/Hamas), terrorism, sanctions or other geopolitical events
globally (including conflict
between Taiwan and China); quarterly fluctuations in
revenues and operating results; difficulties developing new
products that achieve market acceptance; risks associated with
managing international activities (including trade barriers,
particularly with respect to China); absence of long-term
commitments from customers; risks that Astera Labs may
not be able to manage strains associated with its growth; credit
risks associated with its accounts receivable; stock price
volatility; information technology risks, including cyber-attacks
against Astera Labs' products and its networks; and other
risks and uncertainties that are detailed under the caption “Risk
Factors” and elsewhere in our Annual Report on 10-K that will be
filed with the Securities and Exchange Commission (the “SEC”) and
in Quarterly Reports on Form 10-Q filed with the SEC and the
other SEC filings and reports Astera Labs may make from time
to time. Moreover, we operate in a very competitive and
rapidly changing environment, and new risks may emerge from time to
time. It is not possible for our management to predict all risks,
nor can we assess the impact of all factors on our business or the
extent to which any factor(s) may cause actual results or outcomes
to differ materially from those contained in any forward-looking
statements we may make. Accordingly, you should not rely on any of
the forward-looking statements. Astera Labs disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, except as required by law.
About Astera Labs Our PCIe, CXL and Ethernet
semiconductor-based connectivity solutions are purpose-built to
unleash the full potential of accelerated computing at cloud-scale.
Inspired by trusted partnerships with hyperscalers and the data
center ecosystem, we are an innovation leader of products that are
customizable, interoperable, and reliable. Discover how we are
transforming AI and modern data-driven applications at
www.asteralabs.com.
|
ASTERA LABS, INC.CONDENSED CONSOLIDATED
BALANCE SHEETS (Unaudited)(In
thousands) |
|
|
|
December 31,2024 |
|
December 31,2023 |
Assets |
|
|
|
|
Current assets |
|
|
|
|
Cash and cash equivalents |
|
$ |
79,551 |
|
|
$ |
45,098 |
|
Marketable securities |
|
|
834,750 |
|
|
|
104,215 |
|
Accounts receivable, net |
|
|
38,811 |
|
|
|
8,335 |
|
Inventory |
|
|
43,215 |
|
|
|
24,095 |
|
Prepaid expenses and other
current assets |
|
|
16,652 |
|
|
|
4,064 |
|
Total current assets |
|
|
1,012,979 |
|
|
|
185,807 |
|
Property and equipment,
net |
|
|
35,651 |
|
|
|
4,712 |
|
Other assets |
|
|
5,878 |
|
|
|
5,773 |
|
Total assets |
|
$ |
1,054,508 |
|
|
$ |
196,292 |
|
|
|
|
|
|
Liabilities, Redeemable Convertible Preferred Stock and
Stockholders’ Equity (Deficit) |
Current liabilities |
|
|
|
|
Accounts payable |
|
$ |
26,918 |
|
|
$ |
6,337 |
|
Accrued expenses and other
current liabilities |
|
|
59,624 |
|
|
|
28,742 |
|
Total current liabilities |
|
|
86,542 |
|
|
|
35,079 |
|
Other liabilities |
|
|
3,167 |
|
|
|
3,787 |
|
Total liabilities |
|
|
89,709 |
|
|
|
38,866 |
|
Commitments and
contingencies |
|
|
|
|
Redeemable convertible
preferred stock |
|
|
- |
|
|
|
255,127 |
|
Stockholders’ equity
(deficit) |
|
|
|
|
Common stock |
|
|
16 |
|
|
|
4 |
|
Additional paid-in
capital |
|
|
1,173,153 |
|
|
|
27,411 |
|
Accumulated other
comprehensive income |
|
|
426 |
|
|
|
259 |
|
Accumulated deficit |
|
|
(208,796 |
) |
|
|
(125,375 |
) |
Total stockholders’ equity
(deficit) |
|
|
964,799 |
|
|
|
(97,701 |
) |
Total liabilities, redeemable
convertible preferred stock and stockholders’ equity (deficit) |
|
$ |
1,054,508 |
|
|
$ |
196,292 |
|
|
ASTERA LABS, INC.CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS (Unaudited)(In thousands,
except per share amounts) |
|
|
|
Three Months Ended |
|
Years Ended |
|
|
December 31,2024 |
|
September 30,2024 |
|
December 31,2023 |
|
December 31,2024 |
|
December 31,2023 |
Revenue |
|
$ |
141,096 |
|
|
$ |
113,086 |
|
|
$ |
50,514 |
|
|
$ |
396,290 |
|
|
$ |
115,794 |
|
Cost
of revenue |
|
|
36,648 |
|
|
|
25,209 |
|
|
|
11,489 |
|
|
|
93,591 |
|
|
|
35,967 |
|
Gross
profit |
|
|
104,448 |
|
|
|
87,877 |
|
|
|
39,025 |
|
|
|
302,699 |
|
|
|
79,827 |
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
56,524 |
|
|
|
50,659 |
|
|
|
19,654 |
|
|
|
200,830 |
|
|
|
73,407 |
|
Sales
and marketing |
|
|
22,818 |
|
|
|
23,248 |
|
|
|
4,995 |
|
|
|
123,652 |
|
|
|
19,992 |
|
General and administrative |
|
|
24,962 |
|
|
|
22,866 |
|
|
|
5,356 |
|
|
|
94,283 |
|
|
|
15,925 |
|
Total
operating expenses |
|
|
104,304 |
|
|
|
96,773 |
|
|
|
30,005 |
|
|
|
418,765 |
|
|
|
109,324 |
|
Operating income (loss) |
|
|
144 |
|
|
|
(8,896 |
) |
|
|
9,020 |
|
|
|
(116,066 |
) |
|
|
(29,497 |
) |
Interest income |
|
|
10,558 |
|
|
|
10,912 |
|
|
|
1,674 |
|
|
|
34,288 |
|
|
|
6,549 |
|
Income (loss) before income taxes |
|
|
10,702 |
|
|
|
2,016 |
|
|
|
10,694 |
|
|
|
(81,778 |
) |
|
|
(22,948 |
) |
Income tax (benefit) provision |
|
|
(14,011 |
) |
|
|
9,609 |
|
|
|
(3,631 |
) |
|
|
1,643 |
|
|
|
3,309 |
|
Net
income (loss) |
|
$ |
24,713 |
|
|
$ |
(7,593 |
) |
|
$ |
14,325 |
|
|
$ |
(83,421 |
) |
|
$ |
(26,257 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net income
(loss) per share attributable to common stockholders: |
|
|
|
|
Basic |
|
$ |
0.15 |
|
|
$ |
(0.05 |
) |
|
$ |
— |
|
|
$ |
(0.64 |
) |
|
$ |
(0.71 |
) |
Diluted |
|
$ |
0.14 |
|
|
$ |
(0.05 |
) |
|
$ |
— |
|
|
$ |
(0.64 |
) |
|
$ |
(0.71 |
) |
Weighted-average shares used in calculating net income (loss) per
share attributable to common stockholders: |
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
159,895 |
|
|
|
156,831 |
|
|
|
38,627 |
|
|
|
131,262 |
|
|
|
37,131 |
|
Diluted |
|
|
177,559 |
|
|
|
156,831 |
|
|
|
47,636 |
|
|
|
131,262 |
|
|
|
37,131 |
|
|
ASTERA LABS, INC.CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS (Unaudited)(In
thousands) |
|
|
|
Years Ended December 31, |
|
|
|
2024 |
|
|
|
2023 |
|
Cash flows from
operating activities |
|
|
|
|
Net
loss |
|
$ |
(83,421 |
) |
|
$ |
(26,257 |
) |
Adjustments to reconcile net loss to net cash provided by (used in)
operating activities |
|
|
|
|
Stock-based compensation |
|
|
234,588 |
|
|
|
10,679 |
|
Depreciation |
|
|
3,154 |
|
|
|
1,781 |
|
Non-cash operating lease expense |
|
|
2,428 |
|
|
|
1,232 |
|
Warrants contra revenue |
|
|
1,395 |
|
|
|
805 |
|
Inventory write-downs |
|
|
168 |
|
|
|
10,343 |
|
Accretion of discounts on marketable securities |
|
|
(8,341 |
) |
|
|
(1,624 |
) |
Changes in operating assets and liabilities: |
|
|
|
|
Accounts receivable, net |
|
|
(30,480 |
) |
|
|
2,386 |
|
Inventory |
|
|
(19,287 |
) |
|
|
(5,564 |
) |
Prepaid expenses and other assets |
|
|
(13,031 |
) |
|
|
(720 |
) |
Accounts payable |
|
|
20,887 |
|
|
|
(4,264 |
) |
Accrued expenses and other liabilities |
|
|
31,018 |
|
|
|
(167 |
) |
Operating lease liability |
|
|
(2,402 |
) |
|
|
(1,346 |
) |
Net
cash provided by (used in) operating activities |
|
|
136,676 |
|
|
|
(12,716 |
) |
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
Purchases of property and equipment |
|
|
(34,245 |
) |
|
|
(2,761 |
) |
Purchases of marketable securities |
|
|
(930,575 |
) |
|
|
(126,225 |
) |
Sales
and maturities of marketable securities |
|
|
208,665 |
|
|
|
111,214 |
|
Other
investing activities |
|
|
(1,413 |
) |
|
|
— |
|
Net
cash used in investing activities |
|
|
(757,568 |
) |
|
|
(17,772 |
) |
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
Proceeds from issuance of common stock in connection with initial
public offering, net of underwriting discounts and commissions |
|
|
672,198 |
|
|
|
— |
|
Payment of deferred offering costs |
|
|
(4,801 |
) |
|
|
(1,407 |
) |
Proceeds from exercises of
stock options |
|
|
5,458 |
|
|
|
1,115 |
|
Proceeds from employee stock
purchase plan |
|
|
4,160 |
|
|
|
— |
|
Tax
withholding related to net share settlements of restricted stock
units |
|
|
(20,111 |
) |
|
|
— |
|
Repurchase of common stock upon termination |
|
|
(1,066 |
) |
|
|
(210 |
) |
Net
cash provided by (used in) financing activities |
|
|
655,838 |
|
|
|
(502 |
) |
Net
increase (decrease) in cash, cash equivalents, and restricted
cash |
|
|
34,946 |
|
|
|
(30,990 |
) |
Cash, cash equivalents, and restricted cash |
|
|
|
|
Beginning of the period |
|
|
45,098 |
|
|
|
76,088 |
|
End
of the period |
|
$ |
80,044 |
|
|
$ |
45,098 |
|
|
ASTERA LABS, INC.RECONCILIATION OF GAAP TO
NON-GAAP FINANCIAL MEASURES (Unaudited)(In
thousands, except percentages and per share amounts) |
|
|
|
Three Months Ended |
|
Years Ended |
|
|
December 31,2024 |
|
September 30,2024 |
|
December 31,2023 |
|
December 31,2024 |
|
December 31,2023 |
GAAP gross profit |
|
$ |
104,448 |
|
|
$ |
87,877 |
|
|
$ |
39,025 |
|
|
$ |
302,699 |
|
|
$ |
79,827 |
|
Stock-based compensation expense upon IPO (1) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
516 |
|
|
|
— |
|
Stock-based compensation expense |
|
|
131 |
|
|
|
102 |
|
|
|
8 |
|
|
|
329 |
|
|
|
24 |
|
Non-GAAP gross profit |
|
$ |
104,579 |
|
|
$ |
87,979 |
|
|
$ |
39,033 |
|
|
$ |
303,544 |
|
|
$ |
79,851 |
|
|
|
|
|
|
|
|
|
|
|
|
GAAP
gross margin |
|
|
74.0 |
% |
|
|
77.7 |
% |
|
|
77.3 |
% |
|
|
76.4 |
% |
|
|
68.9 |
% |
Stock-based compensation expense upon IPO (1) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.1 |
|
|
|
— |
|
Stock-based compensation expense |
|
|
0.1 |
|
|
|
0.1 |
|
|
|
— |
|
|
|
0.1 |
|
|
|
0.1 |
|
Non-GAAP gross margin |
|
|
74.1 |
% |
|
|
77.8 |
% |
|
|
77.3 |
% |
|
|
76.6 |
% |
|
|
69.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
GAAP
operating income (loss) |
|
$ |
144 |
|
|
$ |
(8,896 |
) |
|
$ |
9,020 |
|
|
$ |
(116,066 |
) |
|
$ |
(29,497 |
) |
Stock-based compensation expense upon IPO (1) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
88,873 |
|
|
|
— |
|
Stock-based compensation expense |
|
|
48,218 |
|
|
|
45,535 |
|
|
|
3,299 |
|
|
|
145,715 |
|
|
|
10,679 |
|
Employer payroll tax related to stock-based compensation from IPO
(2) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,072 |
|
|
|
— |
|
Non-GAAP operating income (loss) |
|
$ |
48,362 |
|
|
$ |
36,639 |
|
|
$ |
12,319 |
|
|
$ |
119,594 |
|
|
$ |
(18,818 |
) |
|
|
|
|
|
|
|
|
|
|
|
GAAP
operating margin |
|
|
0.1 |
% |
|
(7.9)% |
|
|
17.9 |
% |
|
(29.3)% |
|
(25.5)% |
Stock-based compensation expense upon IPO (1) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
22.4 |
|
|
|
— |
|
Stock-based compensation expense |
|
|
34.2 |
|
|
|
40.3 |
|
|
|
6.5 |
|
|
|
36.8 |
|
|
|
9.2 |
|
Employer payroll tax related to stock-based compensation from IPO
(2) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.3 |
|
|
|
— |
|
Non-GAAP operating margin |
|
|
34.3 |
% |
|
|
32.4 |
% |
|
|
24.4 |
% |
|
|
30.2 |
% |
|
(16.3)% |
|
|
|
|
|
|
|
|
|
|
|
GAAP
net income (loss) |
|
$ |
24,713 |
|
|
$ |
(7,593 |
) |
|
$ |
14,325 |
|
|
$ |
(83,421 |
) |
|
$ |
(26,257 |
) |
Stock-based compensation expense upon IPO (1) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
88,873 |
|
|
|
— |
|
Stock-based compensation expense |
|
|
48,218 |
|
|
|
45,535 |
|
|
|
3,299 |
|
|
|
145,715 |
|
|
|
10,679 |
|
Employer payroll tax related to stock-based compensation from IPO
(2) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,072 |
|
|
|
— |
|
Income tax effect (3) |
|
|
(6,439 |
) |
|
|
2,340 |
|
|
|
— |
|
|
|
(8,910 |
) |
|
|
— |
|
Non-GAAP net income (loss) |
|
$ |
66,492 |
|
|
$ |
40,282 |
|
|
$ |
17,624 |
|
|
$ |
143,329 |
|
|
$ |
(15,578 |
) |
|
|
|
|
|
|
|
|
|
|
|
Net
income (loss) per share attributable to common
stockholders: |
|
|
|
|
GAAP
- basic |
|
$ |
0.15 |
|
|
$ |
(0.05 |
) |
|
$ |
— |
|
|
$ |
(0.64 |
) |
|
$ |
(0.71 |
) |
GAAP
- diluted |
|
$ |
0.14 |
|
|
$ |
(0.05 |
) |
|
$ |
— |
|
|
$ |
(0.64 |
) |
|
$ |
(0.71 |
) |
Non-GAAP pro forma - diluted |
|
$ |
0.37 |
|
|
$ |
0.23 |
|
|
$ |
0.12 |
|
|
$ |
0.84 |
|
|
$ |
(0.12 |
) |
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used to compute net income (loss)
per share attributable to common stockholders: |
|
|
|
|
GAAP
- basic |
|
|
159,895 |
|
|
|
156,831 |
|
|
|
38,627 |
|
|
|
131,262 |
|
|
|
37,131 |
|
GAAP
- diluted |
|
|
177,559 |
|
|
|
156,831 |
|
|
|
47,636 |
|
|
|
131,262 |
|
|
|
37,131 |
|
Non-GAAP pro forma - diluted (4) |
|
|
177,559 |
|
|
|
173,832 |
|
|
|
138,527 |
|
|
|
168,913 |
|
|
|
128,022 |
|
____________________
(1) Stock-based compensation expense recognized
in connection with the time-based vesting and settlement of RSUs
that had previously met the time-based vesting condition and for
which the liquidity event vesting condition was satisfied in
connection with our IPO.
(2) Employer payroll taxes related to the
time-based vesting and settlement of RSUs, that had previously met
the time-based vesting condition and for which the liquidity event
vesting condition was satisfied in connection with our IPO.
(3) Income tax effect is calculated based on the
tax laws in the jurisdictions in which we operate and is calculated
to exclude the impact of stock-based compensation expense and
one-off discrete tax adjustments that are unrelated to our core
operating performance. For the three months ended December 31, 2024
and September 30, 2024, the non-GAAP tax benefit rate was 13% and
tax expense rate of 15%, respectively. The adjustments for the
three months ended December 31, 2023 were not material. For the
years ended December 31, 2024, the non-GAAP tax expense rate was 7%
compared to a tax benefit rate of 27% for the year ended December
31, 2023.
(4) We present the non-GAAP pro forma weighted
average shares to provide meaningful supplemental information of
comparable shares for each periods presented. The non-GAAP pro
forma weighted average shares is calculated as follows:
|
|
Three Months Ended |
|
Years Ended |
|
|
December 31,2024 |
|
September 30,2024 |
|
December 31,2023 |
|
December 31,2024 |
|
December 31,2023 |
Shares used to compute GAAP
net income (loss) per share attributable to common stockholders -
diluted |
|
177,559 |
|
156,831 |
|
47,636 |
|
131,262 |
|
37,131 |
Weighted average effect of the
assumed conversion of redeemable convertible preferred stock from
the beginning of the periods |
|
— |
|
— |
|
90,891 |
|
19,165 |
|
90,891 |
Effect of dilutive equivalent
shares |
|
— |
|
17,001 |
|
— |
|
18,486 |
|
— |
Shares used to compute
non-GAAP pro forma net income (loss) per share- diluted |
|
177,559 |
|
173,832 |
|
138,527 |
|
168,913 |
|
128,022 |
|
ASTERA LABS, INC.SUPPLEMENTAL FINANCIAL
INFORMATIONSTOCK-BASED COMPENSATION EXPENSE
(Unaudited)(In thousands) |
|
|
Three Months Ended |
|
Years Ended |
|
December 31,2024 |
|
September 30,2024 |
|
December 31,2023 |
|
December 31,2024 |
|
December 31,2023 |
Cost of revenue |
$ |
131 |
|
$ |
102 |
|
$ |
8 |
|
$ |
845 |
|
$ |
24 |
Research and development |
|
18,808 |
|
|
14,641 |
|
|
2,303 |
|
|
76,427 |
|
|
7,360 |
Sales and marketing |
|
14,671 |
|
|
16,200 |
|
|
681 |
|
|
95,887 |
|
|
2,067 |
General and
administrative |
|
14,608 |
|
|
14,592 |
|
|
307 |
|
|
61,429 |
|
|
1,228 |
Total stock-based compensation
expense (1) |
$ |
48,218 |
|
$ |
45,535 |
|
$ |
3,299 |
|
$ |
234,588 |
|
$ |
10,679 |
____________________
(1) Stock-based compensation expense recognized
during the year ended December 31, 2024 included $88.9 million of
cumulative stock-based compensation expense related to the
time-based vesting and settlement of RSUs that had previously met
the time-based vesting condition and for which the liquidity event
vesting condition was satisfied in connection with our IPO.
IR CONTACT: Leslie
Greenleslie.green@asteralabs.com
Astera Labs (NASDAQ:ALAB)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Astera Labs (NASDAQ:ALAB)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025